Freeline

Freeline is a privately-held clinical-stage biotechnology company focused on AAV based gene therapy targeting the liver.

Freeline's vision is to create better lives for people suffering from chronic systemic diseases using the potential of gene therapy as a one-off curative treatment.

Freeline was founded in 2015 by Professor Amit Nathwani and Markus Hörer. The company is headquartered in Stevenage, England, United Kingdom.

 

Freeline's technology consists of delivering therapeutic DNA into patients via a viral vector. The technology has already been proven to be able to transfer the therapeutic DNA at a good rate into the blood via the liver.

 

Freeline has developed a next generation AAV based gene therapy platform to provide treatments for a wide range of diseases like haemophilia B, Fabry and Gaucher Disease which have previously been underserved and incurable. We are headquartered in the UK and we also have operations in Germany and the US.

 

Freeline is backed by Novo Holdings, Eventide Asset Management, Wellington Management Company, Cowen Healthcare Investments, Acorn Bioventures and others. The company raised an additional $80M in Series C round, brining the round total to $120M. This additional investment brings Freeline's total funding to $236M to date.

 

 

  • Year founded: 2015
  • Funding Info: $236M over 5 Rounds (Latest Funding Type: Series C)
  • Yearly Revenue: NA
  • Employee Size: 201-500
  • Business Valuation: NA
  • City/Town: Stevenage
  • State: England
  • Country: United Kingdom
Related businesses